Advertisement

Search Results

Advertisement



Your search for The A matches 33503 pages

Showing 8951 - 9000


issues in oncology
survivorship

Two Studies Explore the Role of Primary Care Providers in Effective Cancer Care

Communication between patients and their primary care providers is key to ensuring effective cancer care, both before diagnosis and after treatment, according to two recent papers authored by University of Michigan Rogel Cancer Center researchers. Although each study analyzed different stages of...

prostate cancer

Prostate Cancer Screening Using the Stockholm3 Screening Test With MRI-Guided Biopsy

In a Swedish prostate cancer screening trial (STHLM3-MRI) reported in The Lancet Oncology, Nordström et al found that use of the Stockholm3 screening test together with magnetic resonance imaging (MRI)-guided biopsy reduced overdetection of disease while preserving the ability to detect clinically...

hematologic malignancies
lymphoma

Ixazomib/Rituximab/Dexamethasone for Relapsed or Refractory Waldenström’s Macroglobulinemia

In a phase I/II trial (HOVON124/ECWM-R2) reported in the Journal of Clinical Oncology, Kersten et al found that the combination of oral ixazomib with subcutaneous rituximab and dexamethasone showed efficacy in patients with relapsed or refractory Waldenström’s macroglobulinemia, with a manageable...

genomics/genetics

Cancer Predisposition Screening Tool for Predicting Subsequent Malignancies in Childhood Cancer Survivors

In a Canadian study reported in the Journal of Clinical Oncology, Cullinan et al found that the McGill Interactive Pediatric OncoGenetic Guidelines (MIPOGG) tool provided predictive value for risk of subsequent malignant neoplasms in childhood cancer survivors beyond risk associated with treatment...

issues in oncology
colorectal cancer

Japanese Study Examines How Intervention Encourages Screening for Colorectal Cancer Among Patients With Schizophrenia

Cancer is a leading cause of mortality in patients with mental illnesses. Although individuals with mental illnesses are equally as vulnerable to cancer as the general population, they are at a much higher risk of cancer-related mortality. Owing to a lack of early screening in most cases, such...

colorectal cancer

Antihypertensive Medications May Improve Survival Among Patients With Stage I to III Colorectal Cancer

Commonly used blood pressure drugs may improve survival for patients with colorectal cancer, a recent study published by Balkrishnan et al in Cancer Medicine suggests. After reviewing outcomes of almost 14,000 patients with colorectal cancer, researchers determined that angiotensin-converting...

cns cancers

Report Aims to Assess Contemporary Burden of Brain Tumors in the United States

A new study found that incidence rates for malignant brain and other central nervous system (CNS) tumors declined by 0.8% annually during 2008 through 2017 in the United States for all ages combined. The decline was driven by trends in adults, whereas rates have slightly increased by 0.5% to 0.7%...

breast cancer

Does Radiotherapy Reduce the Long-Term Risk of Ipsilateral Breast Recurrence in Women With DCIS Who Underwent Lumpectomy?

In an analysis of long-term outcomes from the phase III NRG/RTOG 9804 trial reported in the Journal of Clinical Oncology, Beryl McCormick, MD, and colleagues found that whole-breast irradiation vs observation was associated with reduced risk of all and invasive ipsilateral breast recurrence at 15...

immunotherapy

Profile of Adverse Events Related to PD-1 and PD-L1 Inhibitor–Based Therapy

In a systematic review and meta-analysis reported in The Lancet Oncology, Zhou et al provided a profile of treatment-related adverse events observed in clinical trials combining PD-1 or PD-L1 inhibitors with chemotherapy, targeted therapy, immunotherapy, and radiotherapy. Study Details The...

hepatobiliary cancer

FDA Approves Ivosidenib for Advanced or Metastatic IDH1-Mutated Cholangiocarcinoma

On August 25, the U.S. Food and Drug Administration (FDA) approved ivosidenib (Tibsovo), a small-molecule inhibitor of isocitrate dehydrogenase-1 (IDH1), for adult patients with previously treated locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation as detected by an FDA-approved ...

pain management

Study Finds Evidence-Based Interventions Added to Screening Did Not Improve Cancer Pain

When added to regular screening and guidelines, evidence-based interventions implemented at the patient, health professional, and service levels did not significantly improve cancer pain, according to research led by Melanie Lovell, MBBS, PhD, Medical Head of Palliative Care at HammondCare and...

ASCO and MASCC/ISOO Publish Joint Guideline on Prevention, Treatment of Salivary Gland Hypofunction and Xerostomia

A new joint ASCO guideline offers clinicians updated evidence-based recommendations for the prevention and treatment of salivary gland hypofunction and xerostomia caused by nonsurgical cancer therapies.1 The guidance was developed together by ASCO and the Multinational Association of Supportive...

covid-19

ASCO Joins Statement Supporting Mandatory Health Employer COVID-19 Vaccination

With COVID-19 case counts rising amid the spread of the Delta variant, ASCO has joined more than 50 health-care professional societies and organizations that represent millions of workers throughout health and long-term care in calling for all health-care employers to require their employees to be...

Leland Chung, PhD, Distinguished Mentor and Urologic Oncology Research Scientist, Dies at 80

Talk to anyone who knew Leland Chung, PhD, and you’ll hear the same descriptions of the famed scientist: warm, humble, gracious, brilliant, innovative. Dr. Chung, who served as Director of the Urologic Oncology Research Program at Cedars-Sinai Cancer in Los Angeles for 12 years and was Professor in ...

breast cancer

I’m a Two-Time Breast Cancer Survivor, and the Experience Has Been Life-Altering

Even before my breast cancer diagnosis in early 2002, the year was shaping up to be life-altering for me and my family. We had moved from Seattle to Houston for a new career opportunity for my husband and were just settling into our new home when I felt a pea-sized nodule in my left breast during a ...

neuroendocrine tumors

Neuroendocrine Tumor Specialist Pamela Kunz, MD, Looks to Promote Equity in the Workforce

In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with Pamela Kunz, MD, Director, Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center. Dr. Kunz is an international leader in the clinical care of patients with neuroendocrine...

breast cancer
immunotherapy

Sacituzumab Govitecan-hziy for Locally Advanced or Metastatic Triple-Negative Breast Cancer

On April 7, 2021, sacituzumab govitecan-hziy was granted regular approval for treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received two or more prior systemic therapies, at least one of them for metastatic disease.1 Sacituzumab...

Marcus Bosenberg, MD, PhD, Named Inaugural Director of Yale Center for Immuno-Oncology

The Yale Center for Immuno-Oncology has announced the appointment of Marcus Bosenberg, MD, PhD, as its inaugural Director. Dr. Bosenberg is Professor of Dermatology, Pathology, and Immunobiology; Co-Leader of the Genomics, Genetics, and Epigenetics Program in Yale Cancer Center; contact principal...

bladder cancer
immunotherapy

Sacituzumab Govitecan-hziy for Locally Advanced or Metastatic Urothelial Cancer

On April 13, 2021, sacituzumab govitecan-hziy was granted accelerated approval to treat patients with locally advanced or metastatic urothelial cancer who had received platinum-containing chemotherapy and either a PD-1 or a PD-L1 inhibitor.1 Supporting Efficacy Data Approval was based on findings...

hematologic malignancies
symptom management

Belumosudil for Chronic Graft-vs-Host Disease

On July 16, 2021, belumosudil, an inhibitor of Rho-associated coiled-coil kinase 2, was approved for the treatment of adult and pediatric patients 12 years and older with chronic graft-vs-host disease after the failure of at least two prior lines of systemic therapy.1 Supporting Efficacy Data...

lung cancer

High Prevalence of Previously Undiagnosed Emphysema Among Individuals Undergoing Low-Dose CT Screening for Lung Cancer

In a prospective cohort study reported in Clinical Imaging, David Steiger, MD, of the Division of Pulmonary, Critical Care and Sleep Medicine, Icahn School of Medicine at Mount Sinai, in New York, and colleagues in the International Early Lung Cancer Action Program (I-ELCAP) identified emphysema in ...

breast cancer

New Guideline Provides Clarity on Timing, Treatment of Axilla in Early-Stage Breast Cancer

ASCO and Ontario Health (Cancer Care Ontario) have collaborated to release a new clinical practice guideline on the management of the axilla in early-stage breast cancer.1 “A lot has changed in the past several years with regard to de-escalating the amount of treatment women are offered in the...

multiple myeloma

Isatuximab-irfc in Relapsed or Refractory Multiple Myeloma

On March 31, 2021, the anti-CD38 monoclonal antibody isatuximab-irfc was approved for use in combination with carfilzomib and dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy.1 Supporting Efficacy Data...

Heather Wakelee, MD, FASCO, Honored With the 2021 Bonnie J. Addario Lectureship Award

GO2 Foundation for Lung Cancer (GO2 Foundation) presented Heather Wakelee, MD, FASCO, with the 2021 Bonnie J. Addario Lectureship Award at the Physicians’ Education Resource 22nd Annual International Lung Cancer Congress on July 30 in Huntington Beach, California. Dr. Wakelee is Professor of...

Vanderbilt University Appoints Karen Winkfield, MD, PhD, Professor of Radiation Oncology

Karen Winkfield, MD, PhD, Executive Director, Meharry-Vanderbilt Alliance, and Ingram Professor of Cancer Research, was recently promoted to Professor of Radiation Oncology at Vanderbilt University Medical Center (VUMC). “Grateful to those who paved the way,” said Dr. Winkfield on Twitter, noting...

Winette van der Graaf, MD, PhD, Named EORTC President-Elect 2021–2024

The European Organisation for Research and Treatment of Cancer (EORTC) has announced that Winette van der Graaf, MD, PhD, will be EORTC President-Elect 2021–2024. Bertrand Tombal, MD, PhD, will remain EORTC President until March 11, 2022, when the EORTC celebrates its 60th anniversary. Dr. van...

global cancer care
breast cancer

Historic, Present, and Future Perspectives on Breast Cancer in Egypt

Breast cancer is the most frequently diagnosed cancer among women around the world, making it a significant public health problem.1 The disease affects both men and women, although it is rare in men, accounting for just 1% of all breast cancer diagnoses in the United States and less than 0.1% of...

lung cancer

Low-Dose CT Screening for Lung Cancer and the Incidental Findings That May Improve Future Health

Every interaction with patients is an opportunity to change the course of their lives. In the context of screening for disease, every encounter is an opportunity to detect the precursors or early changes that signal early pathophysiology. Smoking status and age are the factors that currently...

lymphoma

Axicabtagene Ciloleucel Improves Multiple Clinical Endpoints in Relapsed Follicular Lymphoma

For the treatment of relapsed or refractory follicular lymphoma, updated data from the ZUMA-5 trial, as compared with the findings of the external control cohort of SCHOLAR-5, showed substantial improvement in all key clinical endpoints with axicabtagene ciloleucel, ZUMA-5 investigators reported in ...

hematologic malignancies
head and neck cancer
gynecologic cancers
immunotherapy
symptom management

FDA Pipeline: Reviews for Agents in Acute Graft-vs-Host Disease, Nasopharyngeal and Ovarian Cancers

Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to an agent for the prevention of acute graft-vs-host disease; Breakthrough Therapy designation to an anti–PD-1 monoclonal antibody for the treatment of metastatic nasopharyngeal carcinoma; and Fast Track designation to a ...

survivorship
cost of care
issues in oncology

Study Examines Link Between Obesity in Long-Term Cancer Survivors and Increased Health-Care Utilization and Spending

A new study from the American Cancer Society published by Xuesong Han, PhD, and colleagues in the journal Cancer has found a link between obesity and the substantial economic burden of nearly $20 billion in 2016 among long-term cancer survivors in the United States, with one-third attributable to...

skin cancer
immunotherapy

Patients With Melanoma Previously Treated With PD-1 or MAPK Inhibitors May Be Less Likely to Respond to ACT-TIL Therapy

Patients with metastatic melanoma who were previously treated with PD-1 or MAPK inhibition are significantly less likely to develop durable objective responses to adoptive cell transfer of tumor-infiltrating lymphocytes (ACT-TIL) than patients naive to these treatments, according to a study...

kidney cancer
immunotherapy

Adjuvant Pembrolizumab May Improve Disease-Free Survival in Patients With High-Risk Renal Cell Carcinoma

As reported in The New England Journal of Medicine by Toni K. Choueiri, MD, and colleagues, an interim analysis of the phase III KEYNOTE-564 trial showed improved disease-free survival with adjuvant pembrolizumab vs placebo after nephrectomy in high-risk patients with clear cell renal cell...

solid tumors

Non–Testicular Cancer Mortality Rates in Men With Testicular Cancer in the Cisplatin Era

In a Norwegian population-based study reported in the Journal of Clinical Oncology, Hellesnes et al found that treatment of testicular cancer with platinum-based chemotherapy or radiotherapy was associated with a significant excess of non–testicular cancer mortality compared with the general...

breast cancer

Extended Follow-up of PALOMA-3 Supports Survival Benefit of Palbociclib Plus Fulvestrant in Advanced Breast Cancer

An updated analysis of the PALOMA-3 randomized, placebo-controlled trial demonstrated continued superiority for the combination of palbociclib (CDK4/6 inhibitor) plus fulvestrant over fulvestrant plus placebo in women with hormone receptor–positive, HER2-negative advanced breast cancer whose...

Breakthrough COVID-19 Infection in Vaccinated Health-Care Workers

This week, we’ll be discussing a study that examined rates of breakthrough COVID-19 infection in vaccinated health-care workers. Then, we’ll move on to a report that compared the efficacy of different durations of anastrozole treatment in patients with hormone receptor–positive breast cancer who...

lung cancer

PD-L1–Positive Non–Small Cell Lung Cancer

In this video, Drs. Justin F. Gainor, Ibiayi Dagogo-Jack, and Jyoti D. Patel discuss current therapy options for PD-L1–positive non–small cell lung cancer (NSCLC). Dr. Gainor presents the case of a 65-year-old man with 55-year smoking history who was diagnosed with stage II NSCLC. The faculty...

lung cancer
genomics/genetics

ALK-Positive Non–Small Cell Lung Cancer

In this video, Drs. Justin F. Gainor, Ibiayi Dagogo-Jack, and Jyoti D. Patel discuss current treatment options for ALK fusion–positive non–small cell lung cancer (NSCLC). Dr. Gainor presents the case of a 31-year-old patient with minimal tobacco exposure who was diagnosed with metastatic NSCLC....

lung cancer
genomics/genetics

NTRK Fusion–Positive Non–Small Cell Lung Cancer

In this video, Drs. Justin F. Gainor, Ibiayi Dagogo-Jack, and Jyoti D. Patel discuss the management of NTRK fusion–positive non–small cell lung cancer (NSCLC). Dr. Gainor presents the case of a 44-year-old man with a 5 pack-year history of tobacco exposure who was diagnosed with metastatic NSCLC;...

lung cancer
genomics/genetics

RET Fusion–Positive Non–Small Cell Lung Cancer

In this video, Drs. Justin F. Gainor, Ibiayi Dagogo-Jack, and Jyoti D. Patel discuss the management of RET fusion–positive non–small cell lung cancer (NSCLC). The case presented is a 65-year-old never-smoker patient with metastatic NSCLC who was found to have an EGFR A118V mutation and a KIF5B-RET...

covid-19

FDA Grants Approval to the Pfizer-BioNTech COVID-19 Vaccine

On August 23, the U.S. Food and Drug Administration (FDA) approved the first COVID-19 vaccine. The vaccine has been known as the Pfizer-BioNTech COVID-19 vaccine, and will now be marketed as Comirnaty, for the prevention of COVID-19 disease in individuals aged 16 years and older. The vaccine also...

breast cancer

Caution With Robotically Assisted Surgical Devices for Mastectomy: FDA Safety Communication

The U.S. Food and Drug Administration (FDA) is reminding patients and health-care providers that the safety and effectiveness of robotically assisted surgical devices for use in mastectomy procedures or in the prevention or treatment of breast cancer have not been established. In addition, the FDA...

lymphoma

Excess Cardiovascular Disease Risk in Patients With Early-Stage Lymphoma: Personalizing Radiotherapy Delivery

As reported in the Journal of Clinical Oncology by Cutter et al, an analysis from the UK NCRI RAPID trial of positron-emission tomography (PET)-directed therapy in patients with early-stage Hodgkin lymphoma indicated that the use of involved-field radiotherapy in PET-negative patients who had...

sarcoma

Combination of Lenvatinib and Etoposide/Ifosfamide for Relapsed or Refractory Osteosarcoma

In the phase I/II ITCC-050 trial reported in The Lancet Oncology, Gaspar et al found that the combination of lenvatinib with etoposide/ifosfamide showed antitumor activity, including good progression-free survival outcomes, in patients with relapsed or refractory osteosarcoma. Study Details...

breast cancer

Physical Activity and Cognitive Function Before, During, and After Chemotherapy for Breast Cancer

In a study reported in the Journal of Clinical Oncology, Elizabeth A. Salerno, PhD, MPH, and colleagues found that higher levels of physical activity before and during chemotherapy in women with early-stage breast cancer was associated with better cognitive function outcomes at up to 6 months...

bladder cancer
immunotherapy

FDA Approves Nivolumab for Adjuvant Treatment of Urothelial Carcinoma

On August 19, the U.S. Food and Drug Administration (FDA) approved the anti–PD-1 therapy nivolumab (Opdivo) for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of disease recurrence after undergoing radical resection. This is the first FDA approval for adjuvant...

leukemia
immunotherapy

Outcomes Notably Improving for Adult ALL

Outcomes in adults with acute lymphoblastic leukemia (ALL) are almost rivaling those in pediatric ALL, thanks to the benefits achieved by incorporating blinatumomab and inotuzumab into chemotherapy regimens. New ways of administering the chemotherapy component are also increasing tolerability and...

prostate cancer

Study Examines Association Between Benign Prostatic Hyperplasia and Prostate Cancer

A team of researchers studied the relationship between benign prostatic hyperplasia (BPH) and prostate cancer in 405 men by quantitatively looking at different parts of the prostate tissue on magnetic resonance imaging (MRI). Findings from their analysis were published by Nandalur et al in the...

supportive care
pain management

Early-Phase Study Rediscovers Potential Alternative to Methadone for Cancer Pain

Levorphanol was associated with improved pain and symptom control in patients with advanced cancer, according to data from an early phase I trial, reported by Akhila Reddy, MD, at the 2021 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO)...

lung cancer
immunotherapy

Does Antibiotic Exposure Affect Response to First-Line Chemoimmunotherapy in Patients With NSCLC?

In an international, multicenter study, researchers evaluated the impact of prior and concurrent antibiotic exposure in a cohort of patients with advanced non–small cell lung cancer (NSCLC) treated with first-line chemoimmunotherapy combinations. In contrast to what has been reported in patients...

Advertisement

Advertisement




Advertisement